Latest advances in pancreatic cancer treatment and impact on practice
Latest advances in pancreatic cancer treatment and impact on practice
SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC
CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
RET inhibition in RET aberrant cancers
A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations
Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours
Comment: POLO III trial for metastatic pancreatic cancer
How will ASCO combat cancer disparities?
Chemotherapy-free strategies in treating leukaemia
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy